SGLT2 inhibitors: Their potential reduction in blood pressure

Journal of the American Society of Hypertension

Volumn 9, Issue 1, 2015, Pages 48-53

  Maliha, George ^a   Townsend, Raymond R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Canagliflozin; dapagliflozin; empagliflozin; hypertension

Indexed keywords

SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE REGULATION; COMORBIDITY; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DRUG POTENCY; GLOMERULUS FILTRATION; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HUMAN; KIDNEY INJURY; NATRIURESIS; NEPHRON; OSMOTIC DIURESIS; PRIORITY JOURNAL; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; DIABETIC ANGIOPATHIES; DIURESIS; DRUG EFFECTS; HYPERTENSION; KIDNEY; PATHOPHYSIOLOGY; PHYSIOLOGY;

BLOOD PRESSURE; DIABETIC ANGIOPATHIES; DIURESIS; HUMANS; HYPERTENSION; KIDNEY; NATRIURESIS; SODIUM-GLUCOSE TRANSPORTER 2; VASCULAR STIFFNESS;

EID: 84923108094     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2014.11.001     Document Type: Review

References (64)

1. D.L. Wingard, and E. Barrett-Connor Heart disease and diabetes M.I. Harris, C.C. Cowie, M.P. Stern, E.J. Boyko, G.E. Reiber, P.H. Bennett, Diabetes in America 2nd ed 1995 NIH Washington, DC 429 448
2. M. Ezzati, A.D. Lopez, A. Rodgers, S. Vander Hoorn, and C.J.L. Murray Selected major risk factors and global and regional burden of disease Lancet 360 2002 1347 1360
3. C. Sampanis, and C. Zamboulis Arterial hypertension in diabetes mellitus: from theory to clinical practice Hippokratia 12 2008 74 80
4. J.R. Sowers, M. Epstein, and E.D. Frohlich Diabetes, hypertension, and cardiovascular disease: an update Hypertension 37 2001 1053 1059
5. N.R.C. Campbell, R.E. Gilbert, L.A. Leiter, P. Larochelle, S. Tobe, and A. Chockalingam Hypertension in people with type 2 diabetes: update on pharmacologic management Can Fam Physician 57 2011 e347 e353
6. W.L. Baker, L.R. Smyth, D.M. Riche, E.M. Bourret, K.W. Chamberlin, and W.B. White Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis J Am Soc Hypertens 8 2014 262 275
7. M.R. Law, N.J. Wald, J.K. Morris, and R.E. Jordan Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials BMJ 326 2003 1427
8. D. Vasilakou, T. Karagiannis, E. Athanasiadou, M. Mainou, A. Liakos, and E. Bekiari Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis Ann Intern Med 159 2013 262 274
9. N.J. Bohannon Treatment of vulvovaginal candidiasis in patients with diabetes Diabetes Care 21 1998 451 456
10. M.R. Weir, I. Kline, J. Xie, R. Edwards, and K. Usiskin Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR) Curr Med Res Opin 30 2014 1759 1768
11. C. Vlachopoulos, K. Aznaouridis, M.F. O'Rourke, M.E. Safar, K. Baou, and C. Stefanadis Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis Eur Heart J 31 2010 1865 1871
12. R.V. Oliva, and G.L. Bakris Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors J Am Soc Hypertens 8 2014 330 339
13. B. Zinman, S.E. Inzucchi, J. Lachin, C. Wanner, R. Ferrari, and E. Bluhmki Design of the empagliflozin cardiovascular (CV) outcome event trial in type 2 diabetes (T2D) Can J Diabetes 37 2013 S29 30
14. B. Neal, V. Perkovic, D. de Zeeuw, K.W. Mahaffey, G. Fulcher, and P. Stein Rationale, design, and baseline characteristics of the canagliflozin cardiovascular assessment study (CANVAS)-a randomized placebo-controlled trial Am Heart J 166 2013 217 223
15. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58).Available at: http://clinicaltrials.gov/show/NCT01730534. Accessed July 21, 2014.
16. A. Mather, and C. Pollock Glucose handling by the kidney Kidney Int 79 2011 S1 S6
17. E.M. Wright, Ba Hirayama, and D.F. Loo Active sugar transport in health and disease J Intern Med 261 2007 32 43
18. U. Hjarne A study of orthoglycaemic glycosuria with particular reference to its hereditability Acta Med Scand 67 1927 422 494
19. R. Zietse, and E.J. Hoorn Inhibiting renal sodium-glucose transport in diabetes: pass the salt Kidney Int 76 2009 1293
20. G.L. Bakris, and V.A. Fonseca Response to 'Inhibiting renal sodium-glucose transport in diabetes: Pass the salt' Kidney Int 76 2009 1293
21. W. Meng, B.A. Ellsworth, A.A. Nirschl, P.J. McCann, M. Patel, and R.N. Girotra Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes J Med Chem 51 2008 1145 1149
22. A. Mather, and C. Pollock Renal glucose transporters: novel targets for hyperglycemia management Nat Rev Nephrol 6 2010 307 311
23. R. Santer Molecular analysis of the SGLT2 gene in patients with renal glucosuria J Am Soc Nephrol 14 2003 2873 2882
24. J. Calado, R. Santer, and J. Rueff Effect of kidney disease on glucose handling (including genetic defects) Kidney Int 79 2011 S7 S13
25. G.L. Bakris, V.A. Fonseca, K. Sharma, and E.M. Wright Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications Kidney Int 75 2009 1272 1277
26. H. Rahmoune, P.W. Thompson, J.M. Ward, C.D. Smith, G. Hong, and J. Brown Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes Diabetes 54 2005 3427 3434
27. E. Chin, A.M. Zamah, D. Landau, H. Gronboek, A. Flyvbjerg, and D. LeRoith Changes in facilitative glucose transporter messenger ribonucleic acid levels in the diabetic rat kidney Endocrinology 138 1997 1267 1275
28. H. Osorio, R. Bautista, A. Rios, M. Franco, A. Arellano, and H. Vargas-Robles Effect of phlorizin on SGLT2 expression in the kidney of diabetic rats J Nephrol 23 2010 541 546
29. H.S. Freitas, G.F. Anh, K.F.S. Melo, M.M. Okamoto, M. Oliveira-Souza, and S. Bordin Na+-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity Endocrinology 149 2008 717 724
30. M.P. Majowicz, L.V. Gonzalez Bosc, M.F. Albertoni Borghese, M.F. Delgado, M.C. Ortiz, and N. Sterin Speziale Atrial natriuretic peptide and endothelin-3 target renal sodium-glucose cotransporter Peptides 24 2003 1971 1976
31. H. Osorio, R. Bautista, A. Rios, M. Franco, J. Santamaria, and B. Escalante Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats Diabetes Res Clin Pract 86 2009 e46 e49
32. J.F. List, and J.M. Whaley Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans Kidney Int 79 2011 S20 S27
33. D.Z.I. Cherney, Ba Perkins, N. Soleymanlou, M. Maione, V. Lai, and A. Lee Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus Circulation 129 2014 587 597
34. S. Villafana, F. Huang, and E. Hong Role of the sympathetic and renin angiotensin systems in the glucose-induced increase of blood pressure in rats Eur J Pharmacol 506 2004 143 150
35. M.F. Albertoni Borghese, M.P. Majowicz, M.C. Ortiz, M.F. Delgado, N.B. Sterin Speziale, and N.A. Vidal Renal sodium-glucose cotransporter activity and aquaporin-2 expression in rat kidney during chronic nitric oxide synthase inhibition Nephron Physiol 107 2007 77 86
36. D.E. Kohan, P. Fioretto, W. Tang, and J.F. List Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control Kidney Int 85 2014 962 971
37. J. Yale, G. Bakris, B. Cariou, D. Yue, E. David-Neto, and L. Xi Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease Diabetes Obes Metab 15 2013 463 473
38. V. Woo, M. Davies, D. de Zeeuw, G. Bakris, V. Perkovic, and C. Gassmann-Mayer Canagliflozin is effective and generally well tolerated in subjects with type 2 diabetes mellitus and stage 3 chronic kidney disease Diabetologia 56 2013 S382
39. A. Mithal, A.H. Barnett, J. Manassie, R. Jones, H. Rattunde, and H.J. Worele Empagliflozin in patients with type 2 diabetes mellitus and stage 3A, 3B and 4 chronic kidney disease (CKD) Diabetologia 56 2013 S382
40. A.H. Barnett, A. Mithal, J. Manassie, R. Jones, H. Rattunde, and H.J. Woerle Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial Lancet Diabetes Endocrinol 2 2014 369 384
41. H. Yamout, V. Perkovic, M. Davies, V. Woo, D. de Zeeuw, and C. Mayer Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy Am J Nephrol 40 2014 64 74
42. S. Sha, D. Polidori, T. Heise, J. Natarajan, K. Farrell, and S. Wang Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus Diabetes Obes Metab 16 2014 1087 1095
43. I. Tikkanen, K. Narko, C. Zeller, A. Green, A. Salsali, and U.C. Broedl Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension Diabetes Care 2014 pii: DC-141096. [Epub ahead of print]
44. S.C. Thomson, T. Rieg, C. Miracle, H. Mansory, J. Whaley, and V. Vallon Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat Am J Physiol Regul Integr Comp Physiol 302 2012 R75 R83
45. J.D. Duarte, and R.M. Cooper-DeHoff Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics Expert Rev Cardiovasc Ther 8 2010 793 802
46. P. Van Buren, and R. Toto Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management Adv Chronic Kidney Dis 18 2011 28 41
47. S. Giunti, D. Bartit, and M.E. Cooper Mechanisms of diabetic nephropathy: role of hypertension Hypertension 4 2006 519 526
48. Y. Kanwar, L. Sun, P. Xie, F. Liu, and S. Chen A glimpse of various pathogenetic mechanisms of diabetic nephropathy Annu Rev Pathol 6 2011 395 423
49. L. Gnudi, G. Viberti, L. Raij, V. Rodriguez, D. Burt, and P. Cortes GLUT-1 overexpression: link between hemodynamic and metabolic factors in glomerular injury? Hypertension 42 2003 19 24
50. Y. Wang, K. Heilig, T. Saunders, A. Minto, D.K. Deb, and A. Chang Transgenic overexpression of GLUT1 in mouse glomeruli produces renal disease resembling diabetic glomerulosclerosis Am J Physiol Renal Physiol 299 2010 F99 F111
51. T. Nagata, T. Fukuzawa, M. Takeda, M. Fukazawa, T. Mori, and T. Nihei Tofogliflozin, a novel sodium/glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice Br J Pharmacol 170 2013 519 531
52. N. Terami, D. Ogawa, H. Tachibana, T. Hatanaka, J. Wada, and A. Nakatsuka Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice PloS One 9 2014 e100777
53. V. Vallon, M. Gerasimova, M.A. Rose, T. Masuda, J. Satriano, and E. Mayoux SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic akita mice Am J Physiol Renal Physiol 306 2014 F194 F204
54. A. Tahara, E. Kurosaki, M. Yokono, D. Yamajuku, R. Kihara, and Y. Hayashizaki Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice Eur J Pharmacol 715 2013 246 255
55. N. Koijma, J.M. Williams, T. Takahashi, N. Miyata, and R.J. Roman Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats J Pharmacol Exp Ther 345 2013 464 472
56. V. Vallon, M. Rose, M. Gerasimova, J. Satriano, K.A. Platt, and H. Koepsell Knockout of na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus Am J Physiol Renal Physiol 304 2013 F156 F167
57. D.Z. Cherney, B.A. Perkins, N. Soleymanlou, R. Har, N. Fagan, and O.E. Johansen The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus Cardiovasc Diabetol 13 2014 28
58. S. Theilade, M. Lajer, F. Persson, C. Joergensen, and P. Rossing Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes Diabetes Care 36 2013 715 721
59. J. Bolinder, O. Ljunggren, J. Kullberg, L. Johansson, J. Wilding, and A.M. Langkilde Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin J Clin Endocrinol Metab 97 2012 1020 1031
60. W.J. Kostis, J. Cabrera, W.C. Hooper, P.K. Whelton, M.A. Espeland, and N.M. Cosgrove Relationships between selected gene polymorphisms and blood pressure sensitivity to weight loss in elderly persons with hypertension Hypertension 61 2013 857 863
61. R.H. Unger, and P.E. Scherer Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity Trends Endocrinol Metab 21 2010 345 352
62. L. Blonde, J.P.H. Wilding, J. Chiasson, D. Polidori, G. Meiniger, and P. Stein Canagliflozin (CANA) lowers A1C and blood pressure (BP) through weight loss-independent (WL-I) and weight loss-associated (WL-A) mechanisms Diabetes 62 2013 A288
63. E.S. Schellenberg, D.M. Dryden, B. Vandermeer, C. Ha, and C. Korownyk Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis Ann Intern Med 159 2013 543 551
64. R.W. Koivula, A.B. Tornberg, and P.W. Franks Exercise and diabetes-related cardiovascular disease: systematic review of published evidence from observational studies and clinical trials Curr Diab Rep 13 2013 372 380